-
03:51:12 PM

BLRX Stock News

08/30/23 7:00 AM
Nasdaq : BLRX
earnings
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
-Announced Initiation of Investigator-Initiated Randomized Phase 2 Combination Trial with Motixafortide in First Line PDAC in Collaboration with Columbia University-. "We had a very productive second quarter across all areas of the company, including our focused pre-launch preparation activities tied to the potential U.S. approval of motixafortide in...
RHEA-AI
neutral
07/17/23 7:00 AM
Nasdaq : BLRX
clinical trial
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide
BioLineRx Ltd., a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases, today announced the initiation of a randomized, investigator-initiated Phase 2 clinical trial in first line metastatic pancreatic cancer based on preliminary data from the...
RHEA-AI
positive
04/17/23 11:00 AM
Nasdaq : BLRX
clinical trial
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma
- GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints -- Nature Medicine publication describes how GENESIS trial included patients representative of current multiple myeloma population undergoing autologous HSCT, including older patients and those
RHEA-AI
neutral